A PHASE 1 STUDY TO ASSESS THE RELATIVE BIOAVAILABILITY OF TWO CAPSULE FORMULATIONS OF IXAZOMIB, AN ORAL PROTEASOME INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA

Wednesday, July 26, 2017

Read the Story Here

Related Posts

Discover more posts like this.

PHASE 1 FIRST-IN- HUMAN STUDY OF DALUTRAFUSP ALFA,

Cluster of differentiation (CD)73-adenosine and transforming growth factor (TGF)-β pathways are involved in abrogated antitumor immune responses and can lead to protumor conditions....

Jul 26, 2023

RARE SOLID AND CYSTIC PRESENTATION OF HEMANGIOPERICYTOMA/ SOLITARY FIBROUS TUMOR: A CASE REPORT

Jul 26, 2022

MANUFACTURING-DEPENDENT CHANGE IN BIOLOGICAL ACTIVITY OF THE TLR4 AGONIST GSK1795091

Jul 26, 2022
See All Posts